Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL605432 | 0.81 | TACR1 (0.37) | TACR1RIPK1 | |
| SCHEMBL23925983 | 0.79 | TACR1 (0.36) | TACR1 | |
| SCHEMBL6274182 | 0.76 | GNAI3 (0.41) | TACR1 | |
| SCHEMBL7854892 | 0.73 | TACR1 (0.63) | TACR1 | |
| SCHEMBL586949 | 0.72 | SMN1; SMN2 (0.36) | TACR1 | |
| SCHEMBL29217067 | 0.71 | TACR1 (0.34) | TACR1 | |
| SCHEMBL23499213 | 0.71 | ATM (0.36) | TACR1 | |
| SCHEMBL25368995 | 0.71 | ATM (0.36) | TACR1 | |
| SCHEMBL21748875 | 0.71 | SMYD3 (0.34) | TACR1 | |
| SCHEMBL3649436 | 0.71 | SMYD3 (0.34) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1370568-B1 | CHEMICAL COMPOUNDS | GLAXO GROUP LTD (GB) | 2005-10-12 | — | — | EP | disclosed |
| US-20040162422-A1 | adenosine derivatives having an acetylene group in the 4' position, which are adenosine A1 agonists; treating ischaemic heart disease, peripheral vascular disease or stroke or patient suffering pain, a CNS disorder, sleep apnoea or emesis | HALL ADRIAN (GB) | 2004-08-19 | — | — | US | disclosed |
| EP-1370568-A1 | CHEMICAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2003-12-17 | — | — | EP | disclosed |
| WO-2002074780-A1 | CHEMICAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162422-A1 | adenosine derivatives having an acetylene group in the 4' position, which are adenosine A1 agonists; treating ischaemic heart disease, peripheral vascular disease or stroke or patient suffering pain, a CNS disorder, sleep apnoea or emesis | ADORA1, ADORA2A, ADORA2B | TACR1 729/4885RIPK1 3730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.